A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn  ¹     Brian G. Feagan  ²     Douglas C. Wolf  ³     Geert R. D'Haens  ⁴     Severine Vermeire  ⁵     Stephen B Hanauer  ⁶     Subrata Ghosh  ⁷     Heather Smith  ⁸     Matt Cravets     Paul A. Frohna     Richard Aranda     Sheila Gujrathi     Allan Olson    
¹ University of California,San Diego,United States
² Robarts Research,London,Canada
³ Atlanta Gastroenterology Associates ,Atlanta,United States
⁴ Academic Medical Center,Amsterdam,Netherlands
⁵ University of Leuven,Leuven,Belgium
⁶ Feinberg School of Medicine,Chicago,United States
⁷ University of Calgary,Alberta,Canada
⁸ Receptos,San Diego,

Conference
UEG Week 2015

Citation
United European Gastroenterology Journal; 2015: 2 (Supplement 1)